Lunai Bioworks (NASDAQ:LNAI) Shares Down 5.5% – What’s Next?

Lunai Bioworks Inc. (NASDAQ:LNAI) shares fell 5.5% on Wednesday . The stock traded as low as $3.05 and last traded at $3.09. Approximately 85,021 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 2,477,772 shares. The stock had previously closed at $3.27.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on LNAI shares. Wall Street Zen upgraded shares of Lunai Bioworks to a “sell” rating in a research report on Saturday, May 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Lunai Bioworks in a report on Friday, April 10th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Lunai Bioworks Price Performance

The stock has a 50-day moving average of $2.76 and a 200 day moving average of $4.27. The stock has a market capitalization of $14.50 million, a price-to-earnings ratio of -8.00 and a beta of 0.37.

Lunai Bioworks (NASDAQ:LNAI) last released its earnings results on Friday, May 15th. The company reported ($0.10) earnings per share (EPS) for the quarter. The business had revenue of $0.02 million for the quarter.

Institutional Trading of Lunai Bioworks

An institutional investor recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC purchased a new stake in Lunai Bioworks Inc. (NASDAQ:LNAI) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned 0.87% of Lunai Bioworks as of its most recent SEC filing. 71.41% of the stock is owned by institutional investors and hedge funds.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.